Geographic atrophy (GA) is a leading cause of vision loss in older adults, closely linked to the advanced stages of age-related macular degeneration (AMD). Until recently, treatment options for GA were quite limited. The introduction of Izervay, a promising therapy specifically designed to target geographic atrophy, offers new hope for patients affected by this debilitating condition. In this article, we’ll explore how Izervay treats geographic atrophy, its mechanism of action, benefits, and potential side effects, offering a comprehensive guide for those seeking to understand this innovative treatment.

Geographic atrophy is an advanced form of age-related macular degeneration (AMD) that primarily affects the macula, the central part of the retina responsible for sharp vision. GA occurs when the retinal cells and tissues, such as photoreceptors, retinal pigment epithelium (RPE), and choriocapillaris, degenerate, leading to gradual and permanent vision loss. As GA progresses, patients may notice blind spots in their vision, difficulty reading, and issues with recognizing faces, severely impacting their quality of life. The disease is chronic, progressive, and without intervention, it can lead to significant visual impairment.

Izervay is a breakthrough therapy specifically developed to address the unmet needs of geographic atrophy patients. Manufactured by Astellas, Izervay (avacincaptad pegol) is a complement C5 inhibitor, designed to slow down the progression of GA. Complement C5 is a part of the body’s immune system, which plays a crucial role in the inflammatory processes contributing to GA. By inhibiting complement activation, Izervay helps to protect the retina from further damage and degeneration.

Izervay targets the complement system, a vital component of the body’s immune defense mechanism. Specifically, it inhibits the C5 protein, which is implicated in the inflammatory process contributing to geographic atrophy. The complement pathway is essential for immune responses but can become overactive in certain conditions, including AMD. This overactivity causes chronic inflammation, leading to the destruction of retinal cells.

By blocking the activity of C5, Izervay reduces inflammation and the subsequent cell damage that drives the progression of geographic atrophy. Importantly, this therapy does not restore lost vision but slows the progression of the disease, potentially preserving remaining eyesight and delaying further deterioration.

Izervay offers significant benefits for individuals with GA, particularly in slowing disease progression. Some of the key advantages include:

• Targeted Approach: By specifically targeting the complement system, Izervay focuses on one of the primary causes of retinal damage in GA. This precision therapy helps in reducing further tissue degeneration.
• Slowing Vision Loss: Clinical trials have shown that Izervay significantly slows down the progression of GA, helping patients retain their remaining vision for a longer period. While it is not a cure, it offers a crucial way to delay severe vision loss.
• Less Frequent Injections: Izervay is administered through intravitreal injections (directly into the eye), but the treatment regimen is less frequent than other therapies, reducing the burden on patients and caregivers.
• Potential to Improve Quality of Life: By preserving eyesight, Izervay can help patients maintain their independence, continue activities they enjoy, and improve their overall quality of life.

Izervay is administered as an intravitreal injection, typically given by an ophthalmologist. The treatment is delivered directly into the vitreous, the gel-like substance inside the eye, allowing the drug to reach the retina and exert its therapeutic effects.

Patients usually receive injections once every month during the initial phase of treatment. Depending on the patient’s response, the dosing schedule may be adjusted. Since intravitreal injections are performed in a clinical setting, patients should expect routine follow-up appointments to monitor the progression of GA and assess the treatment’s effectiveness.

Like any medication, Izervay may cause side effects, although not everyone will experience them. The most common side effects associated with Izervay injections include:

• Eye Irritation: Mild irritation, redness, or discomfort may occur following the injection.
• Increased Intraocular Pressure: In some cases, the injection may cause temporary increases in eye pressure, which can lead to discomfort or blurred vision.
• Infection: While rare, there is a risk of infection (endophthalmitis) associated with intravitreal injections. Patients are monitored closely to prevent complications.
• Cataract Formation: In some patients, Izervay may accelerate cataract formation, although this is more common in individuals with pre-existing cataracts.

It’s essential for patients to discuss the risks and benefits of Izervay with their ophthalmologist before starting treatment. Early detection and intervention can help minimize the risk of complications.

Izervay has undergone rigorous clinical trials to assess its safety and efficacy. The pivotal phase III clinical trials, known as the GATHER1 and GATHER2 trials, demonstrated that Izervay could slow the progression of geographic atrophy by up to 27% over a period of 12 months. These results represent a significant advance in GA treatment, offering hope to patients who previously had no effective options to slow the disease.

Moreover, long-term follow-up studies are underway to evaluate the continued effectiveness of Izervay over extended periods and its impact on patients’ quality of life.

Izervay represents a crucial step forward in the treatment of geographic atrophy, offering patients a way to slow the progression of this debilitating disease. By targeting the complement system, Izervay reduces the inflammatory processes that contribute to retinal degeneration. Although it does not reverse existing damage, Izervay helps preserve vision and offers hope to those suffering from GA. With its potential to delay vision loss and maintain quality of life, Izervay is a promising option for individuals seeking to manage this challenging condition.

If you or a loved one has been diagnosed with geographic atrophy, consult with your ophthalmologist to determine if Izervay is an appropriate treatment option for you. Early intervention and tailored care can make a significant difference in the management of this disease.

World Eye Care Foundation’s eyecare.live brings you the latest information from various industry sources and experts in eye health and vision care. Please consult with your eye care provider for more general information and specific eye conditions. We do not provide any medical advice, suggestions or recommendations in any health conditions.